Melanie Lee

Melanie Georgina Lee (born 29 July 1958)[1] is an English pharmaceutical industry executive and a former biomedical researcher.

Career

Research

"Paul and Melanie’s paper started a revolution in cell cycle research."

Kathleen Weston[2]

Lee received an undergraduate degree in Biology from the University of York, working with Simon Hardy,[3] and then a Ph.D. at National Institute for Medical Research in London.[4]

Lee worked as a molecular genetics postdoc, first at Imperial College London on yeast and then from 1985 with Paul Nurse at the ICRF's Lincoln's Inn Laboratories.[2] Nurse's work on the cell cycle won him the Nobel Prize, and in his speech he cited Lee's work on finding a human homologue of the yeast gene cdc2.[5] Nurse said of this work that "I suppose the most astonishing thing was the way Melanie Lee in the lab did it by complementation."[6] Lee later recounted being uncomfortable with the competition in the laboratory.[4]

In 2003, she was elected a Fellow of the Academy of Medical Sciences.[7] She was also Trustee and Deputy Chairman of Cancer Research UK for six years.[8][9]

Works

Business

Lee became CEO of NightstaRx in 2014 and Chief Scientific Officer of BGT Plc in November 2014. She began her pharmaceutical industry career at Glaxo in 1988, leaving academia after she became pregnant. She joined Celltech in 1998 where she was Director of R&D.[10] She held the same role at UCB Pharmaceuticals and was CEO of Syntaxin Ltd from 2010-13.[4][11][12] She was chair of Cancer Research Technology.[8] She is on the board of Lundbeck[1] and founded the Think10 business advice company.[13]

She was an advisor to the 2014-15 Dowling Review of business-university research collaborations.[9]

Recognition

Lee was made a CBE in 2009 for services to medical science.[14][15] In 2014, she was named as one of the top 100 "leading practising scientists" in the UK by the Science Council.[16]

Personal life

She is married to Christopher, with whom she lives in London. They have two sons.[4]

References

  1. 1 2 "Notice of Annual General Meeting". Lundbeck. March 1, 2012. Retrieved September 14, 2015.
  2. 1 2 Weston, Kathleen. "6: Divide and Rule". Blue Skies and Bench Space. Cancer Research UK. Retrieved September 14, 2015.
  3. "Honour for University of York plant biologist". University of York. January 2, 2009. Retrieved September 14, 2015.
  4. 1 2 3 4 Cahoon, Lauren (September 26, 2008). "From Watching 'The Expert' to Becoming An Expert". Science Magazine. doi:10.1126/science.caredit.a0800142. Retrieved September 14, 2015.
  5. Nurse, Paul (2007). "The discovery of cdc2 as the key regulator of the cell cycle". Cells. Jones and Bartlett Publishers. Retrieved September 14, 2015.
  6. Smith, Jim (March 2009). "The cell cycle and beyond: an interview with Paul Nurse". Diseases Models & Mechanisms. 2: 113–5. doi:10.1242/dmm.002592. PMC 2650208Freely accessible. PMID 19259383. Retrieved September 14, 2015.
  7. Dr Melanie Lee CBE FMedSci, Academy of Medical Sciences, retrieved 4 March 2014
  8. 1 2 100 leading UK practising scientists, UK Science Council, retrieved 4 March 2014
  9. 1 2 "Dowling Review Group". Royal Academy of Engineering. Retrieved September 14, 2015.
  10. "Melanie G. Lee CBE, Ph.D., FMedSci, DSc (Hons)". BloombergBusiness. Retrieved September 14, 2015.
  11. "Dr Melanie Lee CBE FMedSci". The Academy of Medical Sciences. Retrieved September 14, 2015.
  12. "Melanie Lee becomes CEO of Syntaxin". MedNous. Evernow Publishing. February 8, 2010. Retrieved September 14, 2015.
  13. "About us". Think10. Retrieved September 14, 2015.
  14. Dr. Melanie Lee, Chairman of CRT, is awarded Commander of the Order of the British Empire (CBE), Cancer Research Technology, retrieved 4 March 2014
  15. "New Year honours list: DBEs and CBEs". The Guardian. December 31, 2008. Retrieved September 14, 2015.
  16. "The UK's 100 leading practising scientists". Times Higher Education. January 17, 2014. Retrieved September 14, 2015.

External links

This article is issued from Wikipedia - version of the 8/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.